CAOA Returns—for the Third Time. Does It Matter More in 2026?

For the third time in four years, Senate Democrats have introduced the Cannabis Administration and Opportunity Act (CAOA), their sweeping proposal to federally legalize cannabis and establish a national regulatory framework. Once again, the legislation seeks to remove marijuana from the Controlled Substances Act, create a pathway for interstate commerce, expunge certain federal convictions, and place the industry under federal oversight.

The bill’s policy goals are familiar. What’s different in 2026 is the political environment in which it returns.

Unlike its previous iterations, the CAOA arrives as the cannabis industry awaits the conclusion of the Drug Enforcement Administration’s Schedule III rescheduling process.

That overlap raises a broader question for operators and investors: Does the bill have a realistic path forward, or is its greatest significance the pressure it could place on the administration pursuing cannabis reform through executive action?

The legislation has changed little

Originally released as a discussion draft in 2021 before being formally introduced in 2022 and again in 2024, the CAOA remains the Senate’s most comprehensive cannabis legalization proposal. The latest version would:

• Remove cannabis from the Controlled Substances Act.
• Preserve states’ authority to determine their own cannabis laws.
• Establish a federal regulatory framework involving agencies, including the FDA and the Alcohol and Tobacco Tax and Trade Bureau (TTB).
• Provide pathways for expungement of certain federal cannabis convictions.
• Expand research and create programs intended to support communities disproportionately affected by prohibition.
• Eliminate the federal tax burden created by Internal Revenue Code Section 280E by ending the federal prohibition.

The legislation was reintroduced by Senators Chuck Schumer, Cory Booker, and Ron Wyden, joined by 16 Democratic co-sponsors. As with previous versions, however, the bill launched without Republican original co-sponsors, making its legislative prospects uncertain in the current Congress.

Why do many operators remain skeptical?

The industry’s cautious reaction is understandable.

Previous versions of the CAOA generated significant attention but never received a Senate floor vote. Since its first unveiling, cannabis operators have watched several major federal reform proposals—including SAFE Banking and broader legalization efforts—stall despite repeated introductions.

For many executives, the latest filing therefore represents less of a legislative breakthrough than another signal of long-term policy ambitions.

That skepticism is reinforced by timing. While Congress debates comprehensive legalization, the DEA is already moving through an administrative process that could produce the most significant federal cannabis policy change in decades if marijuana is ultimately placed in Schedule III.

Why this filing may still matter

Although few observers expect the CAOA to become law in its current form, senior analyst Shadd Dales, CEO and Founder of The Dales Report, argues that its political significance could exceed its legislative prospects.

In it Friday´s edition, The Dales Report reads the bill effectively creates a new point of comparison between congressional legalization and the administration’s administrative reforms.

Rather than viewing the proposal solely through the lens of whether it passes, the publication suggests its reintroduction could increase political pressure to continue advancing cannabis reform through executive action.

Under that view, comprehensive legalization and administrative rescheduling become competing reform tracks rather than competing policy proposals.

Even if Congress fails to advance the CAOA, the existence of a more expansive legalization bill could encourage policymakers to demonstrate continued progress through actions already within executive authority.

Whether that dynamic ultimately materializes remains uncertain. But it reflects that federal cannabis policy is increasingly shaped by both Congress and the executive branch rather than either acting alone.

Congress and the DEA are solving different problems

One reason the debate continues is that the CAOA and the DEA’s rescheduling process address fundamentally different issues.

If finalized, Schedule III would primarily affect cannabis businesses by removing the federal tax penalties associated with Section 280E and reshaping how marijuana is treated under the Controlled Substances Act.

The CAOA goes considerably further.

It would remove cannabis from federal prohibition altogether, establish permanent regulatory authority, create a framework for interstate commerce, address criminal justice provisions, and provide long-term regulatory certainty that administrative rescheduling alone cannot deliver.

In other words, operators should not view the two efforts as substitutes. One is an administrative change within existing federal law; the other would rewrite that law entirely.

The return of the Cannabis Administration and Opportunity Act does not necessarily represent a dramatic shift in congressional cannabis policy. The bill’s core framework remains largely unchanged, and its legislative path remains difficult.

Its importance may instead lie in what it signals about the broader federal reform landscape.

For the first time, comprehensive legalization is being debated alongside an active federal rescheduling process nearing its conclusion. Whether or not the CAOA advances, that dual-track approach means operators, investors, and policymakers are no longer watching a single avenue of reform—they’re watching two.

And in Washington, competing paths toward the same destination can sometimes accelerate the conversation faster than either could alone. Join us at the IgniteIt Washington, D.C. Summit on November 18, where lawmakers, regulators, operators, investors, and legal experts will examine the future of federal legalization, rescheduling, banking, taxation, and the regulatory changes shaping the next chapter of the U.S. cannabis market.